Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, w… Read more
Oncotelic Therapeutics Inc (OTLC) - Total Assets
Latest total assets as of September 2025: $28.16 Million USD
Based on the latest financial reports, Oncotelic Therapeutics Inc (OTLC) holds total assets worth $28.16 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncotelic Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Oncotelic Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncotelic Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Oncotelic Therapeutics Inc's total assets of $28.16 Million consist of 0.5% current assets and 99.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.3% |
| Accounts Receivable | $18.98K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.10 Million | 4.1% |
| Goodwill | $2.79 Million | 10.5% |
Asset Composition Trend (2017–2024)
This chart illustrates how Oncotelic Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncotelic Therapeutics Inc's current assets represent 0.5% of total assets in 2024, a decrease from 7.0% in 2017.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 95.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 10.5% of total assets.
Oncotelic Therapeutics Inc Competitors by Total Assets
Key competitors of Oncotelic Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oncotelic Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oncotelic Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncotelic Therapeutics Inc is currently not profitable relative to its asset base.
Oncotelic Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.01 | 0.06 |
| Quick Ratio | 0.08 | 0.01 | 0.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-18.47 Million | $ -16.12 Million | $ -10.57 Million |
Oncotelic Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Oncotelic Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | -11.1% |
| Total Assets | $26.68 Million |
| Market Capitalization | $13.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncotelic Therapeutics Inc's assets below their book value (0.51 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncotelic Therapeutics Inc's assets decreased by 11.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncotelic Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Oncotelic Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $26.68 Million | -11.12% |
| 2023-12-31 | $30.01 Million | -16.89% |
| 2022-12-31 | $36.12 Million | +52.95% |
| 2021-12-31 | $23.61 Million | -0.21% |
| 2020-12-31 | $23.66 Million | -0.09% |
| 2019-12-31 | $23.68 Million | +2864.30% |
| 2018-12-31 | $799.00K | -31.83% |
| 2017-12-31 | $1.17 Million | -- |